{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T17:27:24Z","timestamp":1780507644331,"version":"3.54.1"},"reference-count":74,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.clml.2025.02.002","type":"journal-article","created":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T00:10:27Z","timestamp":1739319027000},"page":"476-483","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["SOHO State of the Art Updates and Next Questions: Treatment Options for Marginal Zone Lymphoma"],"prefix":"10.1016","volume":"25","author":[{"given":"Maria Cristina","family":"Pirosa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasios","family":"Stathis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5522-6109","authenticated-orcid":false,"given":"Emanuele","family":"Zucca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2025.02.002_bib0001","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.annonc.2019.10.010","article-title":"Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Zucca","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2025.02.002_bib0002","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/bjh.19064","article-title":"Guideline for the diagnosis and management of marginal zone lymphomas: a British Society of Haematology Guideline","volume":"204","author":"Walewska","year":"2024","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2025.02.002_bib0003","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1097\/CCO.0000000000000886","article-title":"Bacterial infection-driven lymphomagenesis","volume":"34","author":"Vannata","year":"2022","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.clml.2025.02.002_bib0004","doi-asserted-by":"crossref","first-page":"4","DOI":"10.21037\/aol-21-3","article-title":"Antibiotic treatment for bacteria-associated extra nodal marginal zone lymphoma","volume":"5","author":"Sassone","year":"2021","journal-title":"Ann Lymphoma"},{"key":"10.1016\/j.clml.2025.02.002_bib0005","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1007\/s10120-021-01172-x","article-title":"Involvement of non-Helicobacter pylori helicobacter infections in Helicobacter pylori-negative gastric MALT lymphoma pathogenesis and efficacy of eradication therapy","volume":"24","author":"Takigawa","year":"2021","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.clml.2025.02.002_bib0006","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1182\/blood-2015-12-624304","article-title":"The spectrum of MALT lymphoma at different sites: biological and therapeutic relevance","volume":"127","author":"Zucca","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.02.002_bib0007","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.6004\/jnccn.2023.0057","article-title":"NCCN Guidelines(R) insights: b-cell lymphomas, version 6.2023","volume":"21","author":"Zelenetz","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.clml.2025.02.002_bib0008","doi-asserted-by":"crossref","first-page":"8018","DOI":"10.1200\/JCO.2005.02.3903","article-title":"Long-term follow-up of gastric MALT lymphoma after Helicobacter pylori eradication","volume":"23","author":"W\u00fcndisch","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2025.02.002_bib0009","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1093\/annonc\/mdn760","article-title":"Long-term outcome following Helicobacter pylori eradication in a retrospective study of 105 patients with localized gastric marginal zone B-cell lymphoma of MALT type","volume":"20","author":"Stathis","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2025.02.002_bib0010","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1093\/annonc\/mdm513","article-title":"Ocular adnexal MALT lymphoma: an intriguing model for antigen-driven lymphomagenesis and microbial-targeted therapy","volume":"19","author":"Ferreri","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2025.02.002_bib0011","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1182\/blood-2013-02-486522","article-title":"Antibiotic therapy in nongastrointestinal MALT lymphoma: a review of the literature","volume":"122","author":"Kiesewetter","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.02.002_bib0012","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1111\/bjh.12703","article-title":"Prevalence of Achromobacter xylosoxidans in pulmonary mucosa-associated lymphoid tissue lymphoma in different regions of Europe","volume":"164","author":"Adam","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2025.02.002_bib0013","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1093\/annonc\/mdu166","article-title":"Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi","volume":"25","author":"Arcaini","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2025.02.002_bib0014","doi-asserted-by":"crossref","first-page":"8447","DOI":"10.3748\/wjg.v22.i38.8447","article-title":"Antiviral therapy of hepatitis C as curative treatment of indolent B-cell lymphoma","volume":"22","author":"Merli","year":"2016","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.clml.2025.02.002_bib0015","doi-asserted-by":"crossref","first-page":"4060","DOI":"10.1200\/JCO.22.00668","article-title":"Direct-acting antivirals as primary treatment for Hepatitis C virus-associated indolent Non-hodgkin lymphomas: the BArT study of the Fondazione Italiana Linfomi","volume":"40","author":"Merli","year":"2022","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.clml.2025.02.002_bib0016","doi-asserted-by":"crossref","first-page":"873","DOI":"10.3390\/cancers14040873","article-title":"Development of organ-preserving radiation therapy in gastric marginal zone lymphoma","volume":"14","author":"Rolf","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clml.2025.02.002_bib0017","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.ijrobp.2020.03.019","article-title":"Involved site radiation therapy in adult lymphomas: an overview of international lymphoma radiation oncology group guidelines","volume":"107","author":"Wirth","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clml.2025.02.002_bib0018","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.radonc.2011.05.013","article-title":"Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trial","volume":"100","author":"Lowry","year":"2011","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.clml.2025.02.002_bib0019","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/S1470-2045(20)30686-0","article-title":"4 Gy versus 24 Gy radiotherapy for follicular and marginal zone lymphoma (FoRT): long-term follow-up of a multicentre, randomised, phase 3, non-inferiority trial","volume":"22","author":"Hoskin","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2025.02.002_bib0020","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/hon.3078","article-title":"Long term outcomes of gastric mucosa-associated lymphoid tissue lymphoma treated with radiotherapy: a multi-center retrospective cohort study","volume":"41","author":"Smith","year":"2023","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.clml.2025.02.002_bib0021","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1182\/bloodadvances.2020003992","article-title":"Involved-site radiotherapy for Helicobacter pylori-independent gastric MALT lymphoma: 26 years of experience with 178 patients","volume":"5","author":"Yahalom","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2025.02.002_bib0022","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ijrobp.2015.01.009","article-title":"Modern radiation therapy for extra nodal lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology Group","volume":"92","author":"Yahalom","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clml.2025.02.002_bib0023","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ejca.2021.05.004","article-title":"Prospective Phase II trial of radiation therapy in localised non-gastric marginal zone lymphoma with prospective evaluation of autoimmunity and Helicobacter pylori status: TROG 05.02\/ALLG NHL15","volume":"152","author":"MacManus","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clml.2025.02.002_bib0024","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1093\/annonc\/mdx025","article-title":"Long-term outcome of 487 patients with early-stage extra-nodal marginal zone lymphoma","volume":"28","author":"Teckie","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2025.02.002_bib0025","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1002\/cam4.2732","article-title":"An international multicenter retrospective analysis of patients with extra nodal marginal zone lymphoma and histologically confirmed central nervous system and dural involvement","volume":"9","author":"Sunderland","year":"2020","journal-title":"Cancer Med"},{"key":"10.1016\/j.clml.2025.02.002_bib0026","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1080\/10428194.2019.1644333","article-title":"Radiation therapy for salivary gland MALT lymphoma: ultra-low dose treatment achieves encouraging early outcomes and spares salivary function( )","volume":"61","author":"Gunther","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2025.02.002_bib0027","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.ijrobp.2013.04.035","article-title":"Low-dose radiation therapy (2 Gy \u00d7 2) in the treatment of orbital lymphoma","volume":"86","author":"Fasola","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clml.2025.02.002_bib0028","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20210012","article-title":"Efficacy of low-dose radiotherapy (2 Gy \u00d7 2) in the treatment of marginal zone and mucosa-associated lymphoid tissue lymphomas","volume":"94","author":"Cerrato","year":"2021","journal-title":"Br J Radiol"},{"key":"10.1016\/j.clml.2025.02.002_bib0029","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1200\/JCO.2016.70.6994","article-title":"Final results of the IELSG-19 randomized trial of mucosa-associated lymphoid tissue lymphoma: improved event-free and progression-free survival with Rituximab plus Chlorambucil versus either Chlorambucil or Rituximab monotherapy","volume":"35","author":"Zucca","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2025.02.002_bib0030","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1182\/blood-2002-11-3496","article-title":"Clinical activity of rituximab in extra nodal marginal zone B-cell lymphoma of MALT type","volume":"102","author":"Conconi","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.02.002_bib0031","doi-asserted-by":"crossref","first-page":"e104","DOI":"10.1016\/S2352-3026(14)00021-0","article-title":"First-line response-adapted treatment with the combination of bendamustine and rituximab in patients with mucosa-associated lymphoid tissue lymphoma (MALT2008-01): a multicentre, single-arm, phase 2 trial","volume":"1","author":"Salar","year":"2014","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2025.02.002_bib0032","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1182\/blood-2017-07-795302","article-title":"Long-term results of a phase 2 study of rituximab and bendamustine for mucosa-associated lymphoid tissue lymphoma","volume":"130","author":"Salar","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.02.002_bib0033","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","article-title":"Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study","volume":"123","author":"Flinn","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.02.002_bib0034","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2025.02.002_bib0035","first-page":"2564","article-title":"IELSG38: phase II trial of front-line chlorambucil plus subcutaneous rituximab induction and maintenance in mucosa-associated lymphoid tissue lymphoma","volume":"109","author":"Stathis","year":"2024","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2025.02.002_bib0036","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1182\/blood-2016-06-720599","article-title":"A phase 2 study of rituximab plus lenalidomide for mucosa-associated lymphoid tissue lymphoma","volume":"129","author":"Kiesewetter","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.02.002_bib0037","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/hon.2271","article-title":"Long-term safety and activity of cladribine in patients with extra nodal B-cell marginal zone lymphoma of the mucosa-associated lymphoid tissue (MALT) lymphoma","volume":"35","author":"Kiesewetter","year":"2017","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.clml.2025.02.002_bib0038","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1111\/bjh.15843","article-title":"Lenalidomide plus rituximab (R(2)) in previously untreated marginal zone lymphoma: subgroup analysis and long-term follow-up of an open-label phase 2 trial","volume":"185","author":"Becnel","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2025.02.002_bib0039","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1182\/blood-2018-02-833608","article-title":"Rituximab monotherapy in splenic marginal zone lymphoma: prolonged responses and potential benefit from maintenance","volume":"132","author":"Kalpadakis","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.02.002_bib0040","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/bjh.12036","article-title":"Rituximab, used alone or in combination, is superior to other treatment modalities in splenic marginal zone lymphoma","volume":"159","author":"Else","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2025.02.002_bib0041","first-page":"2297","article-title":"Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA\/IELSG36 phase II study","volume":"109","author":"Iannitto","year":"2024","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2025.02.002_bib0042","doi-asserted-by":"crossref","first-page":"7515","DOI":"10.1200\/JCO.2018.36.15_suppl.7515","volume":"36","author":"Rummel","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2025.02.002_bib0043","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ctrv.2016.11.016","article-title":"Splenic irradiation for splenomegaly: a systematic review","volume":"53","author":"Zaorsky","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.clml.2025.02.002_bib0044","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1182\/blood-2016-05-714667","article-title":"Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection","volume":"128","author":"Arcaini","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.02.002_bib0045","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1056\/NEJMra2102568","article-title":"Marginal-zone lymphomas","volume":"386","author":"Rossi","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2025.02.002_bib0046","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s00277-013-1865-3","article-title":"Rituximab plus bendamustine is active in pretreated patients with extragastric marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma)","volume":"93","author":"Kiesewetter","year":"2014","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2025.02.002_bib0047","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1182\/blood-2016-10-747345","article-title":"Targeting Bruton tyrosine kinase with ibrutinib in relapsed\/refractory marginal zone lymphoma","volume":"129","author":"Noy","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.02.002_bib0048","doi-asserted-by":"crossref","first-page":"7141","DOI":"10.1182\/bloodadvances.2023010298","article-title":"Phase 3 SELENE study: ibrutinib plus BR\/R-CHOP in previously treated patients with follicular or marginal zone lymphoma","volume":"7","author":"Nastoupil","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2025.02.002_bib0049","doi-asserted-by":"crossref","first-page":"6801","DOI":"10.1182\/bloodadvances.2023010668","article-title":"Safety and efficacy of zanubrutinib in relapsed\/refractory marginal zone lymphoma: final analysis of the MAGNOLIA study","volume":"7","author":"Opat","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2025.02.002_bib0050","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/bjh.18368","article-title":"A phase 2, multicentre, open-label trial (ACE-LY-003) of acalabrutinib in patients with relapsed or refractory marginal zone lymphoma","volume":"199","author":"Strati","year":"2022","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2025.02.002_bib0051","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S0140-6736(21)00224-5","article-title":"Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1\/2 study","volume":"397","author":"Mato","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2025.02.002_bib0052","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/hon.2647","article-title":"Prolonged follow-up on lenalidomide-based treatment for mucosa-associated lymphoid tissue lymphoma (MALT lymphoma)-real-world data from the Medical University of Vienna","volume":"37","author":"Kiesewetter","year":"2019","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.clml.2025.02.002_bib0053","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1200\/JCO.19.00010","article-title":"AUGMENT: a phase III study of Lenalidomide Plus Rituximab versus Placebo Plus Rituximab in relapsed or refractory indolent lymphoma","volume":"37","author":"Leonard","year":"2019","journal-title":"J Clin Oncol"},{"issue":"P1156","key":"10.1016\/j.clml.2025.02.002_bib0054","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1097\/01.HS9.0000847492.88194.df","article-title":"MAGNIFY Phase 3b study of Lenalidomide + Rituximab (R2) followed by maintenance in relapsed\/refractory indolent non-hodgkin lymphoma: complete induction phase analysis","volume":"6","author":"Lansigan","year":"2022","journal-title":"HemaSphere"},{"key":"10.1016\/j.clml.2025.02.002_bib0055","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3324\/haematol.2012.065995","article-title":"A phase II study of lenalidomide in patients with extra nodal marginal zone B-cell lymphoma of the mucosa associated lymphoid tissue (MALT lymphoma)","volume":"98","author":"Kiesewetter","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2025.02.002_bib0056","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.3324\/haematol.2022.281963","article-title":"IELSG40\/CLEO phase II trial of clarithromycin and lenalidomide in relapsed\/refractory extra nodal marginal zone lymphoma","volume":"108","author":"Pirosa","year":"2023","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2025.02.002_bib0057","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1182\/blood-2019-131045","article-title":"A phase I\/II study of Lenalidomide plus Obinutuzumab in relapsed indolent lymphoma","volume":"134","author":"Fowler","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.02.002_bib0058","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1182\/blood.2023021243","article-title":"Three-year follow-up analysis of axicabtagene ciloleucel in relapsed\/refractory indolent non-Hodgkin lymphoma (ZUMA-5)","volume":"143","author":"Neelapu","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.02.002_bib0059","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","article-title":"Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial","volume":"23","author":"Jacobson","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2025.02.002_bib0060","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1038\/s41591-024-02986-9","article-title":"Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study","volume":"30","author":"Morschhauser","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.clml.2025.02.002_bib0061","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1170394","article-title":"Novel targeted drugs for follicular and marginal zone lymphoma: a comprehensive review","volume":"13","author":"Rivero","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.clml.2025.02.002_bib0062","doi-asserted-by":"crossref","first-page":"e327","DOI":"10.1016\/S2352-3026(22)00072-2","article-title":"Odronextamab, a human CD20\u00d7CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial","volume":"9","author":"Bannerji","year":"2022","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2025.02.002_bib0063","doi-asserted-by":"crossref","first-page":"TPS7094","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS7094","article-title":"Phase 3 trial of odronextamab plus lenalidomide versus rituximab plus lenalidomide in relapsed\/refractory (R\/R) follicular lymphoma (FL) and marginal zone lymphoma (MZL; OLYMPIA-5)","volume":"42","author":"Vitolo","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2025.02.002_bib0064","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1182\/blood-2021-153355","article-title":"A phase 1 dose escalation study of igm-2323, a novel anti-CD20 x anti-CD3 IgM T cell engager (TCE) in patients with advanced B-cell malignancies","volume":"138","author":"Budde","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.02.002_bib0065","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1182\/blood-2022-166385","article-title":"Interim results of the phase 1 study of Tnb-486, a novel CD19xCD3 T-cell engager, in patients with relapsed\/refractory (R\/R) B-NHL","volume":"140","author":"Hou","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.02.002_bib0066","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1182\/blood-2024-193022","article-title":"Mosunetuzumab with response-driven lenalidomide augmentation As first-line therapy for symptomatic follicular or marginal zone lymphoma: interim analysis of a Multi-center phase 2 study","volume":"144","author":"Olszewski","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.02.002_bib0067","doi-asserted-by":"crossref","first-page":"3055","DOI":"10.1182\/blood-2023-180473","article-title":"Marsun, a phase III, multicenter, open label, randomized, controlled study investigating Mosunetuzumab-lenalidomide versus Investigator choices in patients with relapsed or refractory marginal zone lymphoma (R\/R MZL)","volume":"142","author":"Thieblemont","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.02.002_bib0068","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1182\/blood-2024-200205","article-title":"Limited duration loncastuximab tesirine induces a high rate of complete responses in patients with relapsed\/refractory marginal zone lymphoma - report of first planned interim futility analysis of a multicenter phase II study","volume":"144","author":"Lossos","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.02.002_bib0069","doi-asserted-by":"crossref","first-page":"4690","DOI":"10.1158\/1078-0432.CCR-20-4842","article-title":"Long-term follow-up of patients with relapsed or refractory non-hodgkin lymphoma treated with venetoclax in a phase I, first-in-Human study","volume":"27","author":"Davids","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2025.02.002_bib0070","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1182\/blood-2023-178841","article-title":"Monotherapy with second-generation BCL2 inhibitor sonrotoclax (BGB-11417) is well tolerated with high response rates in patients with relapsed\/refractory marginal zone lymphoma: data from an ongoing phase 1 study","volume":"142","author":"Tedeschi","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.02.002_bib0071","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s00277-011-1337-6","article-title":"Phase II trial of rituximab plus CVP combination chemotherapy for advanced stage marginal zone lymphoma as a first-line therapy: consortium for Improving Survival of Lymphoma (CISL) study","volume":"91","author":"Kang","year":"2012","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2025.02.002_bib0072","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1200\/JCO.18.00605","article-title":"First-line treatment of patients with indolent non-hodgkin lymphoma or mantle-cell lymphoma with Bendamustine Plus Rituximab versus R-CHOP or R-CVP: results of the BRIGHT 5-year follow-up study","volume":"37","author":"Flinn","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2025.02.002_bib0073","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1182\/bloodadvances.2021006844","article-title":"An international analysis evaluating frontline bendamustine with rituximab in extra nodal marginal zone lymphoma","volume":"6","author":"Alderuccio","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2025.02.002_bib0074","doi-asserted-by":"crossref","first-page":"e699","DOI":"10.1097\/HS9.0000000000000699","article-title":"Immunochemotherapy and maintenance with Obinutuzumab or Rituximab in patients with previously untreated marginal zone lymphoma in the randomized GALLIUM trial","volume":"6","author":"Herold","year":"2022","journal-title":"Hemasphere"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025000540?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025000540?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T13:50:53Z","timestamp":1749477053000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265025000540"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":74,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S2152265025000540"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2025.02.002","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SOHO State of the Art Updates and Next Questions: Treatment Options for Marginal Zone Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2025.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}